Log in

NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News

$54.24
-0.49 (-0.90 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$53.60
Now: $54.24
$54.86
50-Day Range
$52.55
MA: $58.15
$64.22
52-Week Range
$19.88
Now: $54.24
$71.11
Volume282,100 shs
Average Volume625,142 shs
Market Capitalization$3.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Deciphera Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$10.71 per share

Profitability

Net Income$-192,260,000.00

Miscellaneous

Employees112
Market Cap$3.03 billion
Next Earnings Date8/7/2020 (Estimated)
OptionableOptionable

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

How has Deciphera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DCPH stock has increased by 22.1% and is now trading at $54.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Deciphera Pharmaceuticals?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Deciphera Pharmaceuticals.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Deciphera Pharmaceuticals.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) posted its quarterly earnings results on Tuesday, May, 5th. The company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by $0.08. The business had revenue of $0.06 million for the quarter, compared to analysts' expectations of $2.50 million. View Deciphera Pharmaceuticals' earnings history.

What price target have analysts set for DCPH?

16 equities research analysts have issued 1-year target prices for Deciphera Pharmaceuticals' shares. Their forecasts range from $42.00 to $91.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $68.31 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View analysts' price targets for Deciphera Pharmaceuticals.

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

News articles about DCPH stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Deciphera Pharmaceuticals.

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,520,000 shares, an increase of 12.1% from the June 15th total of 3,140,000 shares. Based on an average daily trading volume, of 517,500 shares, the days-to-cover ratio is presently 6.8 days. Currently, 9.7% of the company's shares are short sold. View Deciphera Pharmaceuticals' Current Options Chain.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Viking Therapeutics (VKTX), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), AbbVie (ABBV), Bausch Health Companies (BHC) and Cytokinetics (CYTK).

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
  • Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55)

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $54.24.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $3.03 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.